The Disease Burden of Migraine Patients Receiving Prophylactic Treatments in Korea: a Population-based Claims Database Analysis

Overview

Journal BMC Health Serv Res

Publisher Biomed Central

Specialty Health Services

Date 2022 Jul 12

PMID 35821030

Authors

Seonyoung Park

Sola Han

Hae Sun Suh

Affiliations

Soon will be listed here.

Abstract

Background: Despite guideline recommendations, the limited benefits and failure of prophylactic treatment in patients with migraine have been reported. This study aimed to estimate the incremental burden (i.e., healthcare resource use and cost) of disease in patients who received at least one prophylactic treatment compared to those who did not.

Methods: This study analyzed the Health Insurance Review and Assessment Service database, which covers the entire population of Korea from December 2014 to November 2019. We included adult patients with migraine (≥18 years) who had ≥1 claim with migraine diagnosis (G43) or received ≥1 prescription of triptan or ergotamine between December 2015 and November 2018. We defined two groups: (1) migraine patients who received at least one prophylactic treatment (prophylaxis group) and (2) migraine patients who never received prophylactic treatments (non-prophylaxis group). We performed propensity score matching to balance the baseline covariates between the two groups. In a matched cohort, we estimated healthcare resource use and costs in terms of outpatient visits, outpatient visits to neurologists, emergency department (ED) visits, and hospitalizations.

Results: After matching, 633,709 and 633,709 patients were identified in the prophylaxis and non-prophylaxis groups, respectively. The healthcare resource utilization was significantly higher in the prophylaxis group than in the non-prophylaxis group in terms of the number of outpatient visits (2.34 vs 1.70), outpatient visits to neurologists (2.23 vs 1.61), ED visits (1.07 vs 1.05), and hospitalizations (1.12 vs 1.09) (all P < 0.05). The estimated annual costs per patient were significantly higher in the prophylaxis group than in the non-prophylaxis group for outpatient (102.37 USD vs. 62.46 USD), neurology outpatient (141.80 USD vs. 120.30 USD), and ED visits (550.51 USD vs. 234.14 USD) and hospitalization (817.01 USD vs. 645.97 USD) (all P < 0.001).

Conclusions: Migraine patients who received ≥1 prophylactic treatment had a higher burden of disease than migraine patients who received no prophylaxis. This indicates that despite migraine prophylaxis, the migraine-related disease burden remains high, and more efficient migraine prophylaxis strategies are needed.

Citing Articles

Prevalence of orofacial and head pain: an umbrella review of systematic reviews.

Porporatti A, Schroder A, Lebel A, Moreau N, Guillouet C, Stechman-Neto J J Oral Facial Pain Headache. 2025; 38(3):1-14.

PMID: 39800567 PMC: 11810662. DOI: 10.22514/jofph.2024.022.

Neuroimmunological effects of omega-3 fatty acids on migraine: a review.

Chen T, Yang C, Tsai I, Yang H, Hsu Y, Chang C Front Neurol. 2024; 15:1366372.

PMID: 38770523 PMC: 11103013. DOI: 10.3389/fneur.2024.1366372.

Adjusting for Confounders in Outcome Studies Using the Korea National Health Insurance Claim Database: A Review of Methods and Applications.

Han S, Kim K J Prev Med Public Health. 2023; 57(1):1-7.

PMID: 38013409 PMC: 10861329. DOI: 10.3961/jpmph.23.250.

Burden of migraine in patients attending Belgian headache specialists: real-world evidence from the BECOME study.

Lourens S, Van Deun L, Peeters I, Paemeleire K, Van Dycke A, De Klippel N Acta Neurol Belg. 2023; 123(4):1495-1503.

PMID: 37209257 DOI: 10.1007/s13760-023-02280-4.

The impact of migraine and probable migraine on productivity loss in Korea: A cross-sectional online survey.

Kim Y, Han S, Suh H PLoS One. 2022; 17(11):e0277905.

PMID: 36441801 PMC: 9704660. DOI: 10.1371/journal.pone.0277905.

References

Yu S, Zhang Y, Yao Y, Cao H . Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020; 21(1):53. PMC: 7222520. DOI: 10.1186/s10194-020-01117-2. View

Wang S, Chung C, Chankrachang S, Ravishankar K, Merican J, Salazar G . Migraine disability awareness campaign in Asia: migraine assessment for prophylaxis. Headache. 2008; 48(9):1356-65. DOI: 10.1111/j.1526-4610.2008.01088.x. View

Loder E, Burch R, Rizzoli P . The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012; 52(6):930-45. DOI: 10.1111/j.1526-4610.2012.02185.x. View

Kim B, Chu M, Yu S, Dellagnello G, Han J, Cho S . Burden of migraine and unmet needs from the patients' perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain. 2021; 22(1):45. PMC: 8146656. DOI: 10.1186/s10194-021-01250-6. View

. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2018; 59(1):1-18. DOI: 10.1111/head.13456. View

Song T, Cho S, Kim W, Yang K, Yun C, Chu M . Sex Differences in Prevalence, Symptoms, Impact, and Psychiatric Comorbidities in Migraine and Probable Migraine: A Population-Based Study. Headache. 2019; 59(2):215-223. DOI: 10.1111/head.13470. View

Kim L, Kim J, Kim S . A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014; 36:e2014008. PMC: 4151963. DOI: 10.4178/epih/e2014008. View

Lipton R, Bigal M, Diamond M, Freitag F, Reed M, Stewart W . Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007; 68(5):343-9. DOI: 10.1212/01.wnl.0000252808.97649.21. View

Parikh S, Silberstein S . Preventive Treatment for Episodic Migraine. Neurol Clin. 2019; 37(4):753-770. DOI: 10.1016/j.ncl.2019.07.004. View

10.

Vo P, Fang J, Bilitou A, Laflamme A, Gupta S . Patients' perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018; 19(1):82. PMC: 6131678. DOI: 10.1186/s10194-018-0907-6. View

11.

Delussi M, Vecchio E, Libro G, Quitadamo S, de Tommaso M . Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center. BMC Neurol. 2020; 20(1):256. PMC: 7345518. DOI: 10.1186/s12883-020-01839-5. View

12.

. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11):954-976. PMC: 6191530. DOI: 10.1016/S1474-4422(18)30322-3. View

13.

Silberstein S . Preventive Migraine Treatment. Continuum (Minneap Minn). 2015; 21(4 Headache):973-89. PMC: 4640499. DOI: 10.1212/CON.0000000000000199. View

14.

Kroneman M, Maarse H, Zee J . Direct access in primary care and patient satisfaction: a European study. Health Policy. 2005; 76(1):72-9. DOI: 10.1016/j.healthpol.2005.05.003. View

15.

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

16.

Piccinni C, Cevoli S, Ronconi G, Dondi L, Calabria S, Pedrini A . A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years. J Headache Pain. 2019; 20(1):74. PMC: 6734283. DOI: 10.1186/s10194-019-1027-7. View

17.

Meyers J, Davis K, Lenz R, Sakai F, Xue F . Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data. Cephalalgia. 2019; 39(12):1518-1534. DOI: 10.1177/0333102419851855. View

18.

Polson M, Williams T, Speicher L, Mwamburi M, Staats P, Tenaglia A . Concomitant medical conditions and total cost of care in patients with migraine: a real-world claims analysis. Am J Manag Care. 2020; 26(1 Suppl):S3-S7. DOI: 10.37765/ajmc.2020.42543. View

19.

Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner T . Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain. 2018; 19(1):10. PMC: 5794675. DOI: 10.1186/s10194-018-0839-1. View

20.

. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017; 16(11):877-897. PMC: 5641502. DOI: 10.1016/S1474-4422(17)30299-5. View